Значение редокс-статуса коэнзима Q10 как биомаркера окислительного стресса

The article examines the role of ubiquinone as a redox molecule whose functions consist in electron transport in the mitochondrial respiratory chain and regeneration of endogenous antioxidants. Changes in electron redox pathways cause uncontrolled release of reactive oxygen species, which leads to oxidative stress and development of pathologies. The objective of the study was to determine the content of coenzyme Q10 and its redox status in the human body as a biomarker of oxidative stress in various pathologies. This was achieved by assessing and consolidating data on changes in concentrations of the oxidized, reduced ubiquinone forms and total ubiquinone in various pathologies. Total serum ubiquinone was reduced in patients with chronic heart failure (0.68 μmol/L) compared with the control group (0.97 μmol/L). The redox status, expressed as the [ubiquinol]/ [ubiquinone] concentration ratio, decreased in patients with coronary heart disease (0.49 ± 0.34), diabetes (0.26 ± 0.16) compared with the healthy subjects (1.23–1.41). A negative correlation with malonic dialdehyde was observed. The authors analysed the possibility of assessing the efficacy of statin therapy by plasma ubiquinone concentration in patients. Patients with hyperlipidemia who received statins showed a statistically significant reduction in ubiquinol concentration after taking the drug (from 0.81 to 0.46 μg/mL) and the [ubiquinone]/[total ubiquinone] ratio (from 11 to 10 %), which confirms the potential mechanism of statinassociated muscle injury development. Thus, coenzyme Q10 redox status, as well as the concentrations of oxidized, reduced and total ubiquinone can be effective biomarkers of oxidative stress in cardiovascular diseases, diabetes, as well as an important indicator in evaluating the efficacy of hyperlipidemia treatment.Рассмотрена роль убихинона как редокс-молекулы, функциями которой являются перенос электронов в дыхательной цепи митохондрии и регенерация эндогенных антиоксидантов. Изменение редокс-путей электронов вызывает неконтролируемую выработку активных форм кислорода, что приводит к окислительному стрессу и развитию патологий. Цель работы — выявление содержания коэнзима Q10 и значения его редокс-статуса в организме как биомаркера окислительного стресса при различных патологиях, для чего были оценены и обобщены данные о динамике концентраций окисленной, восстановленной формы и общего убихинона при различных патологиях. Содержание общего убихинона в сыворотке крови пациентов с хронической сердечной недостаточностью было снижено (0,68 мкмоль/л) по сравнению с контрольной группой (0,97 мкмоль/л). Редокс-статус, выраженный как отношение концентрации [убихинол]/[убихинон], снижался у пациентов с ишемической болезнью сердца (0,49 ± 0,34), диабетом (0,26 ± 0,16) по сравнению со здоровыми лицами (1,23–1,41). При этом наблюдалась отрицательная корреляция с малоновым диальдегидом. Проведен анализ возможности оценки эффективности статинотерапии по содержанию убихинона в плазме крови пациентов. У пациентов с гиперлипидемией, получавших статины, были достоверно снижены концентрация убихинола после приема препарата (с 0,81 до 0,46 мкг/мл) и соотношение [убихинон]/[общий убихинон] (с 11 до 10 %), что подтверждает потенциальный механизм возникновения статин-ассоциированных поражений мышц. Таким образом, редокс-статус коэнзима Q10, а также концентрация окисленного, восстановленного и общего убихинона могут быть эффективными биомаркерами окислительного стресса при сердечно-сосудистых заболеваниях, диабете, а также важным показателем при оценке эффективности лечения гиперлипидемии

Evaluation of Coenzyme Q10 Redox Status as a Biomarker of Oxidative Stress

The article examines the role of ubiquinone as a redox molecule whose functions consist in electron transport in the mitochondrial respiratory chain and regeneration of endogenous antioxidants. Changes in electron redox pathways cause uncontrolled release of reactive oxygen species, which leads to oxidative stress and development of pathologies. The objective of the study was to determine the content of coenzyme Q10 and its redox status in the human body as a biomarker of oxidative stress in various pathologies. This was achieved by assessing and consolidating data on changes in concentrations of the oxidized, reduced ubiquinone forms and total ubiquinone in various pathologies. Total serum ubiquinone was reduced in patients with chronic heart failure (0.68 μmol/L) compared with the control group (0.97 μmol/L). The redox status, expressed as the [ubiquinol]/ [ubiquinone] concentration ratio, decreased in patients with coronary heart disease (0.49 ± 0.34), diabetes (0.26 ± 0.16) compared with the healthy subjects (1.23–1.41). A negative correlation with malonic dialdehyde was observed. The authors analysed the possibility of assessing the efficacy of statin therapy by plasma ubiquinone concentration in patients. Patients with hyperlipidemia who received statins showed a statistically significant reduction in ubiquinol concentration after taking the drug (from 0.81 to 0.46 μg/mL) and the [ubiquinone]/[total ubiquinone] ratio (from 11 to 10 %), which confirms the potential mechanism of statinassociated muscle injury development. Thus, coenzyme Q10 redox status, as well as the concentrations of oxidized, reduced and total ubiquinone can be effective biomarkers of oxidative stress in cardiovascular diseases, diabetes, as well as an important indicator in evaluating the efficacy of hyperlipidemia treatment

THE MODERN METHODS OF ANALYSIS OF OXIDIZED AND REDUCED FORMS OF COENZYME Q₁₀ IN BIOMATERIAL (REVIEW)

In the human body, coenzyme Q10 is in the oxidized and reduced forms and can be found in every organ. The review describes modern HPLC methods of coenzyme Q10 analysis using electrochemical, spectrophotometric and mass spectrometric detectors. In the article we present information on sampling, preparation of biomaterial for analysis and preservation of coenzyme Q10 stability in biomaterial. It is carried out a comparative analysis of the determination methodologies for the oxidized and reduced forms of coenzyme Q10 by its sensitivity and selectivity

Differences in the pharmacokinetics of ibuprofen in monoand multi-component drugs

The article reports the results of the study which investigated the pharmacokinetics of mono- and multi-component ibuprofen-containing drugs following single oral administration to healthy volunteers. Plasma concentration of ibuprofen was determined by HPLC with spectrophotometric detection. The main pharmacokinetic parameters - Cmax, Tmax, AUC0-t, AUC0-¥, MRT, Kel, TЅ - were calculated after single oral administration of the tested drugs. The pharmacokinetics of Ibuprofen/mono and Ibuprofen (pitofenone+fenpiverinium bromide) after single administration did not demonstrate any statistically significant differences, while the combination drug Ibuprofen/paracetamol did have statistically significant differences in pharmacokinetics as compared to the monocomponent Ibuprofen drug

Различия в фармакокинетике ибупрофена в моно- и многокомпонентных препаратах

The article reports the results of the study which investigated the pharmacokinetics of mono- and multi-component ibuprofen-containing drugs following single oral administration to healthy volunteers. Plasma concentration of ibuprofen was determined by HPLC with spectrophotometric detection. The main pharmacokinetic parameters - Cmax, Tmax, AUC0-t, AUC0-¥, MRT, Kel, TЅ - were calculated after single oral administration of the tested drugs. The pharmacokinetics of Ibuprofen/mono and Ibuprofen (pitofenone+fenpiverinium bromide) after single administration did not demonstrate any statistically significant differences, while the combination drug Ibuprofen/paracetamol did have statistically significant differences in pharmacokinetics as compared to the monocomponent Ibuprofen drug.Представлены результаты исследования фармакокинетики моно- и комбинированных препаратов ибупрофена после однократного перорального приема здоровыми добровольцами. Определена концентрация ибупрофена в плазме крови с помощью метода высокоэффективной жидкостной хроматографии со спектрофотометрическим детектированием. Рассчитаны основные фармакокинетические параметры после однократного приема внутрь изучаемых препаратов: Cmax, Tmax, AUC0-t, AUC0-¥, MRT, Kel, TЅ. Показано, что фармакокинетика препаратов Ибупрофен/моно и Ибупрофен/(питофенон+фенпивериния бромид) после однократного приема не имеет статистически значимых различий, тогда как комбинированный препарат Ибупрофен/парацетамол имеет статистически значимые различия фармакокинетики по сравнению с монопрепаратом ибупрофена

Coenzyme Q10 in Metabolic syndrome

Metabolic syndrome (MS) has become a global health issue due to affect a high percentage of people in most of the countries. MS can be defined as the presence of three of the following factors: obesity, high triglyceride and cholesterol levels, low HDL cholesterol, high blood pressure or high fasting plasma glucose. All these factors increase the risk of cardiovascular disease, diabetes type II, some kind of cancers, sleep abnormalities or physical incapacity among other. Several factors have been identified in the aetiology of MS such as dietary patterns, sedentary lifestyle, genetic background, microbiota, socioeconomic status or age. Different treatments have been proposed for the treatment of MS, but, until today, there is no efficient solution. CoQ10 has emerged as a potential way in MS treatment endorsed by several clinical trials have shown improvements in lipid profile, glucose control, insulin homeostasis and hypertension control in MS patients. The molecular mechanism that could explain these improvements would be the antioxidant capacity of CoQ10 inhibiting oxidative stress that it is present in MS. Additionally, the proportion of CoQ10H2 could be also a crucial role in the protection again MS components. Furthermore, CoQ10 administration could be also helpful in the management of mitochondrial dysfunction associated to MS